StocksFundsScreenerSectorsWatchlists
VERV

VERV - Verve Therapeutics, Inc. Stock Price, Fair Value and News

6.93USD-0.21 (-2.94%)Delayed as of 17 Apr 2024, 02:05 pm ET

Market Summary

VERV
USD6.93-0.21
Delayedas of 17 Apr 2024, 02:05 pm
-2.94%

VERV Stock Price

View Fullscreen

VERV RSI Chart

VERV Valuation

Market Cap

585.3M

Price/Earnings (Trailing)

-2.93

Price/Sales (Trailing)

49.78

EV/EBITDA

-2.07

Price/Free Cashflow

-3.68

VERV Price/Sales (Trailing)

VERV Profitability

EBT Margin

-1606.14%

Return on Equity

-33.37%

Return on Assets

-26.58%

Free Cashflow Yield

-27.14%

VERV Fundamentals

VERV Revenue

Revenue (TTM)

11.8M

Rev. Growth (Yr)

340.98%

Rev. Growth (Qtr)

65.03%

VERV Earnings

Earnings (TTM)

-200.1M

Earnings Growth (Yr)

-17.69%

Earnings Growth (Qtr)

-5.67%

Breaking Down VERV Revenue

52 Week Range

6.7821.42
(Low)(High)

Last 7 days

-18.4%

Last 30 days

-48.3%

Last 90 days

-42.3%

Trailing 12 Months

-54.8%

How does VERV drawdown profile look like?

VERV Financial Health

Current Ratio

17.24

VERV Investor Care

Shares Dilution (1Y)

32.79%

Diluted EPS (TTM)

-3.12

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20234.4M6.8M9.3M11.8M
20220001.9M
20210000

Tracking the Latest Insider Buys and Sells of Verve Therapeutics, Inc.

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Apr 02, 2024
nickerson joan
sold
-12,475
8.24
-1,514
chief administrative officer
Apr 01, 2024
nickerson joan
acquired
-
-
3,315
chief administrative officer
Dec 01, 2023
yeshwant krishna
bought
18,000,000
10.00
1,800,000
-
Nov 29, 2023
dorval allison
acquired
-
-
1,875
chief financial officer
Nov 29, 2023
dorval allison
sold
-6,343
11.45
-554
chief financial officer
Sep 18, 2023
adelman burt a
gifted
-
-
37,168
-
Sep 18, 2023
adelman burt a
gifted
-
-
-37,168
-
Aug 11, 2023
adelman burt a
gifted
-
-
266,258
-
Aug 11, 2023
adelman burt a
gifted
-
-
-266,258
-
Dec 14, 2022
bellinger andrew
acquired
103,320
2.87
36,000
cso & cmo

1–10 of 50

Which funds bought or sold VERV recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Apr 10, 2024
Green Alpha Advisors, LLC
added
11.51
19,421
331,203
0.24%
Apr 05, 2024
CWM, LLC
added
13.33
-
-
-%
Apr 05, 2024
NBC SECURITIES, INC.
unchanged
-
-1,000
1,000
-%
Apr 05, 2024
GAMMA Investing LLC
added
664
8,613
9,641
-%
Mar 28, 2024
Newbridge Financial Services Group, Inc.
new
-
30,417
30,417
0.01%
Mar 27, 2024
NOMURA HOLDINGS INC
added
4.95
24,905
265,919
-%
Mar 22, 2024
PNC FINANCIAL SERVICES GROUP, INC.
new
-
29,190
29,190
-%
Mar 11, 2024
VANGUARD GROUP INC
added
13.22
12,193,500
76,278,700
-%
Mar 05, 2024
PBCay One RSC Ltd
new
-
95,684
95,684
0.02%
Mar 01, 2024
GOLDMAN SACHS GROUP INC
added
360
10,479,000
13,204,400
-%

1–10 of 46

Are Funds Buying or Selling VERV?

Are funds buying VERV calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own VERV
No. of Funds

Unveiling Verve Therapeutics, Inc.'s Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
vanguard group inc
6.81%
5,471,930
SC 13G/A
Jan 29, 2024
ark investment management llc
8.74%
7,025,116
SC 13G/A
Jan 29, 2024
blackrock inc.
5.6%
4,435,481
SC 13G
Jan 23, 2024
state street corp
4.81%
3,866,764
SC 13G/A
Dec 11, 2023
fmr llc
-
0
SC 13G/A
Dec 11, 2023
gv 2017, l.p.
7.6%
6,108,442
SC 13G/A
Feb 14, 2023
singer james r
8.1%
5e+06
SC 13G/A
Feb 14, 2023
casdin capital, llc
3.7%
2,290,571
SC 13G/A
Feb 13, 2023
arch venture fund x, l.p.
-
0
SC 13G/A
Feb 10, 2023
blackrock inc.
5.8%
3,594,074
SC 13G

Recent SEC filings of Verve Therapeutics, Inc.

View All Filings
Date Filed Form Type Document
Apr 03, 2024
4
Insider Trading
Apr 02, 2024
8-K
Current Report
Feb 27, 2024
10-K
Annual Report
Feb 27, 2024
8-K
Current Report
Feb 27, 2024
S-8
Employee Benefits Plan
Feb 16, 2024
4
Insider Trading
Feb 16, 2024
4
Insider Trading
Feb 16, 2024
4
Insider Trading
Feb 16, 2024
4
Insider Trading
Feb 16, 2024
4
Insider Trading

Peers (Alternatives to Verve Therapeutics, Inc.)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
39.7B
6.8B
-0.04% -27.89%
-8.41
5.79
-64.45% -156.37%
22.4B
152.6K
-0.77% 465779.94%
-2.4K
146.8K
- -9.98%
18.5B
1.8B
-1.63% -28.69%
-42.01
10.12
76.23% 61.08%
17.2B
2.4B
8.39% -9.36%
102.31
7.09
15.42% 18.43%
11.9B
3.7B
-8.82% -29.04%
20
3.23
8.87% 75.42%
MID-CAP
6.2B
396.6M
-8.69% -36.86%
-11.82
15.75
425.83% 18.94%
4.4B
-
-8.20% 68.33%
-6.81
60.35
54.84% -34.79%
3.3B
270.6M
-8.92% -2.36%
-13.62
12.04
440.80% -27.84%
2.9B
240.7M
-16.30% -24.47%
-9.88
12.18
-1.03% -92.09%
2.8B
726.4M
-7.52% -11.77%
-45.95
3.88
40.45% 71.62%
SMALL-CAP
1.8B
398.2M
-3.36% -14.10%
25.63
4.6
85.90% -14.05%
557.0M
983.7M
-24.76% -57.93%
-1.02
0.57
-50.36% 17.16%
432.8M
881.7K
-5.56% 294.36%
-9.7
466.16
-77.61% -5.33%
225.3M
4.9M
-10.24% -14.54%
-1.67
46.29
-54.97% 51.72%
6.8M
2.1M
86.67% 92.16%
-0.25
2.14
-13.45% 66.37%

Verve Therapeutics, Inc. News

Latest updates
MarketBeat2 hours ago
Defense World13 Apr 202409:11 am
Yahoo Movies UK13 Apr 202406:00 am
Seeking Alpha02 Apr 202407:00 am

Verve Therapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32021Q4
Revenue65.0%5,144,0003,117,0002,093,0001,404,0001,166,500929,000-
Operating Expenses6.6%59,092,00055,451,00060,676,00059,663,00048,722,00044,789,00032,540,000
  S&GA Expenses5.1%12,281,00011,686,00013,416,00012,553,00011,438,5009,592,0006,601,000
  R&D Expenses7.0%46,811,00043,765,00047,260,00047,110,00037,283,50035,197,00025,939,000
EBITDA Margin19.8%-15.60-19.44-28.18-41.72-79.61--
Income Taxes-52.2%32,00067,000200,000-53,000--
Earnings Before Taxes-5.8%-48,320,000-45,691,000-53,807,000--41,032,000-45,190,000-
EBT Margin19.5%-16.06-19.96-28.93-42.64-81.06--
Net Income-5.7%-48,352,000-45,758,000-53,983,000-51,975,000-41,085,000-45,190,000-31,337,000
Net Income Margin17.9%-17.02-20.72-35.35-48.57-81.09--
Free Cashflow-233.0%-42,865,000-12,872,000-50,624,000-52,471,000-37,860,000-31,812,000-29,024,000
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22020Q4
Assets22.9%75361258963467967332434938441142778.00
  Current Assets28.0%63849847351856356229932936739442074.00
    Cash Equivalents163.1%20678.0070.0084.0011527773.0091.0070.001483879.00
  Net PPE8.2%23.0021.0021.0021.0019.0015.0012.0011.007.007.006.004.00
Liabilities0.8%15315212412512812528.0018.0027.0026.0021.0017.00
  Current Liabilities7.0%37.0035.0033.0034.0035.0029.0026.0015.0022.0020.009.007.00
Shareholder's Equity30.2%600460465509551548296331357385405-63.91
  Retained Earnings-9.7%-544-495-450-396-344-303-257-217-186-155-132-66.54
  Additional Paid-In Capital19.5%1,1439579169068968525555495445405383.00
Shares Outstanding28.6%82.0064.0062.0062.0062.0057.0049.0049.0027.0020.008.002.00
Float---940---557,600---2,185-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22019Q4
Cashflow From Operations-244.4%-40,680-11,811-47,962-49,096-32,892-29,175-26,758-33,507-28,043-21,355-13,341-15,141-14,975-6,324--
  Share Based Compensation4.9%9,2548,8259,0138,0246,7045,9205,6504,2032,7582,2931,351670442213--
Cashflow From Investing24.9%-8,893-11,83433,02515,392-168,313-55,5167,78260,092-56,985-212,31618,48911,71411,887-2,718--
Cashflow From Financing455.7%177,38331,9231,2332,03839,598288,4084455051,224-867282,90193,8318.00---

VERV Income Statement

2023-12-31
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Income Statement [Abstract]   
Collaborations revenue$ 11,758$ 1,941$ 0
Operating expenses:   
Research and development184,946130,09568,202
General and administrative49,93637,53318,865
Total operating expenses234,882167,62887,067
Loss from operations(223,124)(165,687)(87,067)
Other income (expense):   
Change in fair value of antidilution rights liability00(25,574)
Change in fair value of success payment liability1651,486(7,815)
Interest and other income, net23,1666,867142
Total other income (expense), net23,3318,353(33,247)
Loss before provision for income taxes(199,793)(157,334)(120,314)
Provision for income taxes(275)(53)0
Net loss$ (200,068)$ (157,387)$ (120,314)
Net loss per common share, basic$ (3.12)$ (2.91)$ (4.48)
Net loss per common share, diluted$ (3.12)$ (2.91)$ (4.48)
Weighted-average common shares used in net loss, basic64,175,13754,023,65326,872,036
Weighted-average common shares used in net loss, diluted64,175,13754,023,65326,872,036
Comprehensive Loss:   
Net Income (Loss)$ (200,068)$ (157,387)$ (120,314)
Other comprehensive loss:   
Unrealized gain (loss) on marketable securities966(466)(236)
Comprehensive loss$ (199,102)$ (157,853)$ (120,550)

VERV Balance Sheet

2023-12-31
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 206,180$ 115,412
Marketable securities417,770439,396
Collaboration receivable5,8971,012
Prepaid expenses and other current assets8,1027,339
Total current assets637,949563,159
Property and equipment, net22,50518,778
Restricted cash4,7744,824
Operating lease right-of-use assets85,29591,877
Other long term assets2,165585
Total assets752,688679,223
Current liabilities:  
Accounts payable6,6362,424
Accrued expenses20,17820,767
Operating lease obligations, current portion10,19211,904
Total current liabilities37,00635,095
Long-term lease liability64,71570,014
Deferred revenue, non-current48,55620,014
Success payment liability2,7202,885
Other long term liabilities189283
Total liabilities153,186128,291
Commitments and contingencies (See Note 7 and 8)
Stockholders' equtiy  
Preferred stock, $0.001 par value; 5,000,000 shares authorized, no shares issued and oustanding00
Common stock, $0.001 par value; 200,000,000 shares authorized, 81,969,693 and 61,730,816 shares issued and outstanding at December 31, 2023 and 2022, respectively8262
Additional paid-in capital1,143,453895,801
Accumulated other comprehensive loss272(694)
Accumulated deficit(544,305)(344,237)
Total stockholders' equity599,502550,932
Total liabilities and stockholders' equity$ 752,688$ 679,223
VERV
Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
 CEO
 WEBSITEvervetx.com
 INDUSTRYBiotechnology
 EMPLOYEES204

Verve Therapeutics, Inc. Frequently Asked Questions


What is the ticker symbol for Verve Therapeutics, Inc.? What does VERV stand for in stocks?

VERV is the stock ticker symbol of Verve Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Verve Therapeutics, Inc. (VERV)?

As of Tue Apr 16 2024, market cap of Verve Therapeutics, Inc. is 585.26 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of VERV stock?

You can check VERV's fair value in chart for subscribers.

What is the fair value of VERV stock?

You can check VERV's fair value in chart for subscribers. The fair value of Verve Therapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Verve Therapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for VERV so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Verve Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether VERV is over valued or under valued. Whether Verve Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Verve Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for VERV.

What is Verve Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 16 2024, VERV's PE ratio (Price to Earnings) is -2.93 and Price to Sales (PS) ratio is 49.78. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. VERV PE ratio will change depending on the future growth rate expectations of investors.